Review
Published · Updated · 1 min read
Sodium valproate is contraindicated in POLG-related diseases because of liver failure risk
What it means for practice
In POLG-related mitochondrial diseases, account for the contraindication to sodium valproate because of hepatocellular failure risk. Management involves symptom-directed care and prevention of complications.
Summary
Clinical spectrum
This review addresses the role of the POLG gene in mitochondrial diseases and their neurological and extraneurological manifestations. The abstract lists epilepsy, ataxia, and hepatic involvement among manifestations associated with POLG variants. The clinical spectrum described therefore extends beyond neurological symptoms: the review also covers extraneurological disturbances associated with these diseases.
Sodium valproate safety
The article specifically emphasizes that sodium valproate is contraindicated because of the risk of hepatocellular failure. This is the key medication safety warning in the supplied abstract, relevant to the management of patients with POLG-related diseases and epilepsy.
Diagnosis and management
The article discusses diagnostic approaches, clinical presentations, and management strategies, including multidisciplinary care and preventive measures. No curative treatment currently exists. However, management of individual symptoms and preventive strategies may help limit complications. The approaches described therefore focus on controlling manifestations and preventing complications rather than curing the disease.
Source
-
Polymérase gamma : un gène impliqué dans de nombreuses formes de maladies mitochondriales.
Reviewed by: DrugCard editorial team ·
This article does not replace clinical judgement. Disclaimer
